Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
25.26
+1.30 (5.43%)
At close: May 12, 2025, 4:00 PM
25.17
-0.09 (-0.36%)
After-hours: May 12, 2025, 7:59 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
159
Market Cap
18.76B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SMMT News
- 10 days ago - Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire
- 14 days ago - Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
- 17 days ago - What's Going On With Summit Therapeutics Stock On Friday? - Benzinga
- 17 days ago - Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China - Business Wire
- 18 days ago - Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 - Business Wire
- 19 days ago - Why Is Summit Therapeutics Stock Soaring On Wednesday? - Benzinga
- 19 days ago - Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China - Business Wire